Zacks Investment Research upgraded Beigene Ltd (ADR) (NASDAQ:BGNE) to Hold in a statement released earlier today.
- Updated: October 16, 2016
Zacks Investment Research has upgraded Beigene Ltd (ADR) (NASDAQ:BGNE) to Hold in a statement released on 10/11/2016.
On 9/21/2016, Maxim Group released a statement about Beigene Ltd (ADR) (NASDAQ:BGNE) upped the target price from $0.00 to $41.00 that suggested an upside of 0.31%.
Having a price of $32.18, Beigene Ltd (ADR) (NASDAQ:BGNE) traded -1.38% lower on the day. With the last stock price up 7.43% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. BGNE has recorded a 50-day average of $30.79 and a two hundred day average of $29.34. Trade Volume was up over the average, with 160,709 shares of BGNE changing hands over the typical 75,217
Recent Performance Chart
Beigene Ltd (ADR) has with a one year low of $22.51 and a one year high of $35.60 and has a market capitalization of $0.
General Company Details For Beigene Ltd (ADR) (NASDAQ:BGNE)
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton's tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.